Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 3/20 | 0.39 |
| ▸ | IDH2 | P48735 | 3/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5107029 | 0.91 | CHRM3 (0.41) | IDH2CHRM3MEN1KMT2AL3MBTL1 | |
| SCHEMBL5099275 | 0.90 | IDH2 (0.41) | IDH2CHRM3MEN1LMNAKMT2A | |
| SCHEMBL5103316 | 0.88 | CHRM3 (0.43) | CNR1FABP4IDH2CHRM3FABP5 | |
| SCHEMBL5113237 | 0.88 | FABP4 (0.41) | FABP4IDH2FABP5MEN1LMNA | |
| SCHEMBL5107027 | 0.87 | CHRM3 (0.45) | IDH2CHRM3 | |
| SCHEMBL5103918 | 0.85 | FABP4 (0.39) | FABP4IDH2CHRM3FABP5LMNA | |
| Trifluoroacetic Acid SCHEMBL5099366 | 0.84 | CNR1 (0.45) | CNR1FABP4IDH2FABP5MEN1 | |
| SCHEMBL5106874 | 0.84 | CHRM3 (0.46) | CHRM3 | |
| SCHEMBL5112043 | 0.84 | CHRM3 (0.48) | CNR1IDH2CHRM3MEN1KMT2A | |
| SCHEMBL5111796 | 0.83 | AKR1C3 (0.42) | IDH2CHRM3MEN1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | LAINE DRAMANE I | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | CNR1 98/4885FABP4 4255/4885IDH2 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.